Key facts
- This page summarizes Roy Galvin's Form 4 filing for HAEMONETICS CORP (HAE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Nov 2022, 16:54.
Roy Galvin - 01 Nov 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)
- Reporting relationship
- President, Global Plasma & BC
- Issuer ticker
- HAE
- Reported as of
- 01 Nov 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Nov 2022, 16:54:38 UTC
- Prior SEC filing
- 17 Oct 2022
- Next SEC filing
- 17 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas V. Powers, attorney-in-fact for Mr. Galvin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Roy Galvin filed Form 4 for HAEMONETICS CORP (HAE) on 03 Nov 2022.
Change
- Previous filing in this sequence was filed on 17 Oct 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HAE
transaction
Common Stock
Award
- Transaction value
- Shares
- +2,382
- Change %
- Price
- Shares after
- 2,382
- Date
- 01 Nov 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HAE
transaction
Derivative
Non-qualified Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +5,263
- Change %
- Price
- $0.000000
- Shares after
- 5,263
- Date
- 01 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,263
- Exercise price
- $83.96
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
Footnote F2
Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Footnote F3
Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.